Deals
If AbbVie Wants Shire’s Low Tax Rate, Price May Go Up
This article is for subscribers only.
AbbVie Inc. wants a new legal home with a lower tax rate. To make the move, the drugmaker may have to raise its offer for Shire Plc yet again.
AbbVie, the North Chicago, Illinois-based maker of the top-selling arthritis drug Humira, made a fourth offer yesterday to buy Shire Plc for 30.1 billion pounds ($51.6 billion). The offer values the Dublin-based company 48 percent higher than before AbbVie first approached Shire in May.